Products
bioTheranostics provides molecular diagnostic tests that improve the classification of cancer and support physicians in determining a more specific breast cancer prognosis or individual risk of recurrence for patients. All tests are real time, RT-PCR based assays that are compatible with readily available, formalin-fixed paraffin embedded (FFPE) needle core biopsies, excisional biopsies, and/or surgical samples.
|
CancerTYPE ID® provides molecular classification of uncertain or unknown cancers. |
|
|
Breast Cancer IndexSM predicts breast cancer recurrence risk based on proprietary molecular biomarkers. |
|
|
The KRAS Test identifies mutations in the KRAS oncogene to help determine anti-EGFR therapy responsiveness. |
|
|
The BRAF Test identifies mutations in the BRAF oncogene to help determine anti-EGFR therapy responsiveness. |
+1 (877) 886-6739 client services
